143 related articles for article (PubMed ID: 30824955)
21. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.
Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
Cancer; 1994 May; 73(9):2296-304. PubMed ID: 8168033
[TBL] [Abstract][Full Text] [Related]
23. Cefepime monotherapy for febrile neutropenia in patients with lung cancer.
Saito H; Takahashi K; Okuno M; Saka H; Imaizumi K; Hasegawa Y; Tanikawa Y; Yamamoto M; Taniguchi H; Shindoh J; Suzuki R; Shimokata K;
J Infect Chemother; 2014 Jun; 20(6):365-9. PubMed ID: 24679653
[TBL] [Abstract][Full Text] [Related]
24. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
26. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.
Fehér C; Rovira M; Soriano A; Esteve J; Martínez JA; Marco F; Carreras E; Martínez C; Fernández-Avilés F; Suárez-Lledó M; Mensa J
J Antimicrob Chemother; 2014 Sep; 69(9):2556-62. PubMed ID: 24855125
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of meropenem as an empirical treatment for febrile neutropenia in children with cancer.
Pancharoen C; Mekmullica J; Buranachonapa J; Trongjit D; Nuchprayoon I; Vanichsetakul P; Seksarn P; Thisyakorn U
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S174-8. PubMed ID: 12929986
[TBL] [Abstract][Full Text] [Related]
28. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
Malik I; Shaharyar
J Pak Med Assoc; 2002 Jan; 52(1):15-8. PubMed ID: 11963577
[TBL] [Abstract][Full Text] [Related]
29. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Aguilar-Guisado M; Espigado I; Martín-Peña A; Gudiol C; Royo-Cebrecos C; Falantes J; Vázquez-López L; Montero MI; Rosso-Fernández C; de la Luz Martino M; Parody R; González-Campos J; Garzón-López S; Calderón-Cabrera C; Barba P; Rodríguez N; Rovira M; Montero-Mateos E; Carratalá J; Pérez-Simón JA; Cisneros JM
Lancet Haematol; 2017 Dec; 4(12):e573-e583. PubMed ID: 29153975
[TBL] [Abstract][Full Text] [Related]
30. Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial.
Torfoss D; Fladhagen T; Holte H; Brinch L; Schjesvold FH; Fløisand Y; Nyquist E; Dalgaard J; Meyer P; Lehmann AK; Hammerstrøm J; Skjelbakken T; Høiby EA; Sandvik L; Kvaløy S
Clin Microbiol Infect; 2017 Mar; 23(3):179-187. PubMed ID: 27793737
[TBL] [Abstract][Full Text] [Related]
31. Comparing the efficacy of ceftazidime and meropenem in treatment of febrile neutropenia in pediatric patients with cancer.
Ferdosian F; Ghiliyan R; Hashemi A; Akhondzadeh B; Gholampoor E
Iran J Ped Hematol Oncol; 2013; 3(3):103-7. PubMed ID: 24575280
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of early de-escalation of empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large academic medical center.
Ly WJ; Brown EE; Pedretti Z; Auten J; Wilson WS
J Oncol Pharm Pract; 2023 Mar; 29(2):305-310. PubMed ID: 34927495
[TBL] [Abstract][Full Text] [Related]
33. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
34. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
[TBL] [Abstract][Full Text] [Related]
36. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
[TBL] [Abstract][Full Text] [Related]
37. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
38. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
39. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
